- Home
- Companies
- IMB Dx, Inc.
- Products
- AlphaLiquid - Model Cell-free DNA ...
AlphaLiquid - Model Cell-free DNA (cfDNA) -Platform
Cell-free DNA (cfDNA) is circulating fragments of DNA that is released from cells into the circulatory system throughout the body. Tumor cells also release DNA into the blood stream, which is called circulation-tumor DNA(ctDNA). IMBdx Inc.’s AlphaLiquid® platform offers industry-leading ctDNA-based precision diagnostics solutions across the full continuum of cancer care, from therapy selection(AlphaLiquid® 10/100/500) to recurrence and minimal residual disease(MRD) monitoring (AlphaLiquid® Detect), and early stage screening (AlphaLiquid® Screening).
Liquid biopsy uses body fluids such as blood, cerebrospinal fluid, pleural effusion and urine to analyze trace amounts of ctDNA shed by tumor cells. Analysis of ctDNA can yield clinically actionable information to identify druggable targets, monitor therapy response, detect recurrence or screen for early-stage cancer.
Unlike tissue biopsies which involve invasive surgical procedures to obtain tumor tissue, liquid biopsies are based on non-invasive collection of body fluids such as a simple blood draw.
- Minimally Invasive Specimen Collection
- Reflection of Tumor Heterogeneity
- Mutation-based Therapy Matching
- Non-invasive procedures for repeat testing and real-time monitoring of tumor remission and progression
- Captures tumor heterogeneity for more effective precision therapy strategy
- ctDNA progression precedes radiological progression by a significant lead time, enabling earlier detection
- When tumor tissue is difficult to obtain
- When patient is in treatment and requires response monitoring
- When patient is in treatment and requires examination of resistance mutations
- After surgery, to evaluate the need for adjuvant therapy
- After surgery, as a surveillance tool to detect recurrence earlier
- When screening for early-stage cancer
The AlphaLiquid® platform provides industry-leading ctDNA-based precision diagnostics solutions across all stages of cancer for patients, survivors and high-risk individuals.